
09:48 EDT Agomab (AGMB) Therapeutics NV trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AGMB | AgomAb Therapeutics NV ADR | 5.72 | -9.19 | -61.64% |
| Name | Price | % Change | |
|---|---|---|---|
| $5.72 | -61.64% |

09:48 EDT Agomab (AGMB) Therapeutics NV trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks

09:38 EDT Agomab (AGMB) Therapeutics NV trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing

An update from AgomAb Therapeutics NV ADR ( ($AGMB) ) is now available. On October 13, 2026, Agomab announced that the first patient has been dosed in NOV-ERA, its global

AgomAb Therapeutics NV ADR ( ($AGMB) ) just unveiled an update. On October 1, 2026, Agomab reported positive topline data from the 48-week open-label extension of its Phase 2a STENOVA

Agomab (AGMB) announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with Fibrostenosing Crohn’s disease or FSCD, a severe manifestation of

An update from AgomAb Therapeutics NV ADR ( ($AGMB) ) is now available. On September 14, 2026, Agomab Therapeutics reported topline Phase 1 data for AGMB‑447 in patients with idiopathic

AgomAb Therapeutics NV ADR ( ($AGMB) ) has provided an announcement. On September 11, 2026, Agomab Therapeutics announced that shareholders at a Special and Extraordinary General Shareholders’ Meeting in Antwerp

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Agomab (AGMB) with an Overweight rating and $60 price target The company’s ontunisertib is “poised for success” in fibrostenotic Crohn’s disease, the

Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Agomab (AGMB) with an Overweight rating. Agomab’s two-asset pipeline offers multiple 2H26 value inflection points, with ontunisertib’s STENOVA extension providing longer-term safety

Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Agomab (AGMB) with an Overweight rating. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.